New Rhein Funds II and III have invested in seven companies developing proprietary drug/device platforms for the treatment of COPD, BPH, COVID-19, migraine etc.
Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company’s first product candidate is a prodrug of treprostinil delivered on a proprietary transdermal patch to treat pulmonary arterial hypertension (PAH).
American Injectables is a US-based sterile injectable manufacturer of injectable drug products for the US hospital market. The company’s product line includes small molecule 505(b)(2) NDA and 505(j) ANDA syringe and vial products, and it serves as an outsourced contract manufacturing partner for strategic pharmaceutical companies.
Prior investments have included medicines for Alzheimer’s disease, ophthalmic disorders, respiratory disease, and molecular oncology diagnostics.